Bronnen:
- Shitara K, Ozguroglu M, Bang YJ et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. The Lancet, 4 juni 2018. https://doi.org/10.1016/S0140-6736(18)31257-1